Organization
Kyowa Kirin
84 clinical trials
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisStatus: Completed, Estimated PCD: 2019-12-10
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisStatus: Completed, Estimated PCD: 2019-12-03
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UCStatus: Completed, Estimated PCD: 2018-09-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.Status: Terminated, Estimated PCD: 2019-05-10
Clinical trial
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2015-01-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian CancerStatus: Terminated, Estimated PCD: 2012-11-01
Clinical trial
A Phase 1, Uncontrolled, Open-label, Non-randomized, Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors, Followed by an Uncontrolled, Randomized Study in Patients With Esophageal Cancer or Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-11-30
Clinical trial
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal CancerStatus: Completed, Estimated PCD: 2010-01-01
Clinical trial
A Phase 2, Open-label Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisStatus: Completed, Estimated PCD: 2019-11-26
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)Status: Completed, Estimated PCD: 2020-02-06
Clinical trial
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2012-07-01
Clinical trial
A Randomized, Open-Label, Replicate Treatment, 2-Part, Crossover Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches Manufactured at Different Sites.Status: Completed, Estimated PCD: 2021-12-22
Clinical trial
A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar PustulosisStatus: Completed, Estimated PCD: 2021-08-11
Clinical trial
A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationStatus: Terminated, Estimated PCD: 2022-08-26
Clinical trial
An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaStatus: Completed, Estimated PCD: 2015-01-28
Clinical trial
A Clinical Trial of KRN125 to Mobilize Hematopoietic Stem Cells Into Peripheral Blood in Patients With Multiple Myeloma and Malignant LymphomaStatus: Completed, Estimated PCD: 2022-10-25
Clinical trial
A Phase 3, Placebo-controlled, Double-blind Comparative Study of KHK4827 With an Open-label Extension Period in Subjects With Systemic Sclerosis Who Have Moderate to Severe Skin ThickeningStatus: Active (not recruiting), Estimated PCD: 2020-10-16
Clinical trial
A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic SclerosisStatus: Active (not recruiting), Estimated PCD: 2019-01-31
Clinical trial
A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Single-Dose or Open-Label Multiple-Dose Study of KHK4083 in Healthy Adults and Subjects With Ulcerative ColitisStatus: Completed, Estimated PCD: 2017-12-26
Clinical trial
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaStatus: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe PreeclampsiaStatus: Completed, Estimated PCD: 2023-05-17
Clinical trial
A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma and Roll Over Study for Subjects Who Have Participated in ME-401-004 StudyStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2017-08-30
Clinical trial
A Phase 3, Long-term, Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisStatus: Completed, Estimated PCD: 2022-06-27
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2016-12-22
Clinical trial
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-02-12
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.Status: Terminated, Estimated PCD: 2008-10-01
Clinical trial
A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated OsteomalaciaStatus: Completed, Estimated PCD: 2017-07-27
Clinical trial
A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.Status: Completed, Estimated PCD: 2007-03-01
Clinical trial
A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs SyndromeStatus: Completed, Estimated PCD: 2006-08-01
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2Status: Terminated, Estimated PCD: 2012-12-01
Clinical trial
A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyStatus: Completed, Estimated PCD: 2003-10-01
Clinical trial
A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's DiseaseStatus: Completed, Estimated PCD: 2006-07-01
Clinical trial
A Pharmacokinetic Study of KW-6356 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2020-03-20
Clinical trial
Effect of Mild Hepatic Impairment (Child-Pugh Class A) on the Single-dose Pharmacokinetics of IstradefyllineStatus: Completed, Estimated PCD: 2014-12-01
Clinical trial
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell LymphomaStatus: Completed, Estimated PCD: 2017-03-01
Clinical trial
An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial CarcinomaStatus: Terminated, Estimated PCD: 2022-11-15
Clinical trial
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2017-04-20
Clinical trial
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001Status: Completed, Estimated PCD: 2012-09-01
Clinical trial
Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2018-08-22
Clinical trial
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's DiseaseStatus: Completed, Estimated PCD: 2016-10-01
Clinical trial
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2013-11-01
Clinical trial
A Phase I, Open-Label, Dose-escalation, Multicentre Study of KW-2478 Administered as a Single Agent Intravenously in a Consecutive Dosing Schedule in Patients With Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2010-08-01
Clinical trial
A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.Status: Completed, Estimated PCD: 2005-11-01
Clinical trial
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects With Previously Treated Peripheral T-Cell LymphomaStatus: Completed, Estimated PCD: 2012-09-01
Clinical trial
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)Status: Completed, Estimated PCD: 2015-08-01
Clinical trial
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple MyelomaStatus: Terminated, Estimated PCD: 2011-05-01
Clinical trial
A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.Status: Completed, Estimated PCD: 2005-11-01
Clinical trial
Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects With Previously Treated Advanced Solid TumorStatus: Completed, Estimated PCD: 2010-08-01
Clinical trial
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356 Following a Single Oral Dose in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2019-10-02
Clinical trial
Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy SubjectsStatus: Completed, Estimated PCD: 2014-08-01
Clinical trial
A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/CarbidopaStatus: Completed, Estimated PCD: 2003-10-01
Clinical trial
Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination With Mogamulizumab in Adult Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2019-12-15
Clinical trial
A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Istradefylline in Recreational Drug UsersStatus: Completed, Estimated PCD: 2016-07-01
Clinical trial
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.Status: Completed, Estimated PCD: 2005-10-01
Clinical trial
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous LeukemiaStatus: Terminated, Estimated PCD: 2010-04-01
Clinical trial
Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2017-12-08
Clinical trial
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-10-30
Clinical trial
A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyStatus: Completed, Estimated PCD: 2003-05-01
Clinical trial
A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseStatus: Completed, Estimated PCD: 2017-12-20
Clinical trial
An Open-Label Study of KW-2871 Administered With a Premedication Regimen in Patients With Advanced Stage IV MelanomaStatus: , Estimated PCD: 2005-10-01
Clinical trial
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)Status: Terminated, Estimated PCD: 2008-04-01
Clinical trial
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of Sancuso® (Granisetron Transdermal System) Compared to Placebo and Moxifloxacin in Healthy Men and WomenStatus: Completed, Estimated PCD: 2009-08-01
Clinical trial
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked HypophosphatemiaStatus: Completed, Estimated PCD: 2011-12-01
Clinical trial
A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2017-05-01
Clinical trial
A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy SubjectsStatus: Completed, Estimated PCD: 2010-04-01
Clinical trial
Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)Status: Completed, Estimated PCD: 2015-05-01
Clinical trial
A Study to Assess the Pharmacokinetics, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and Intravenous Granisetron in Healthy SubjectsStatus: Completed, Estimated PCD: 2009-05-01
Clinical trial
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked HypophosphatemiaStatus: Completed, Estimated PCD: 2013-05-01
Clinical trial
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked HypophosphatemiaStatus: Completed, Estimated PCD: 2013-09-01
Clinical trial
A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer PatientsStatus: Completed, Estimated PCD: 2008-12-01
Clinical trial
An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic PurpuraStatus: Completed, Estimated PCD: 2006-11-01